Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a corporate governance notification regarding share capital.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the static share capital position as of December 29, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, contingencies, or unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under the Financial Conduct Authority's rules.
Important Facts for Investors
- Issued Share Capital: As of December 29, 2017, the Company had 5,372,553,820 ordinary shares of 25 pence each.
- Treasury Shares: 414,605,950 ordinary shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,957,947,870.
- Regulatory Use: This voting rights figure is the required denominator for shareholders to determine if they must notify the market of their interest or changes thereto.